肺胀宁煎联合抗生素治疗慢性阻塞性肺疾病急性加重期临床观察

Clinical Observation on Feizhangning Decoction Combined with Antibiotics in the Treatment of Acute Exacerbation Chronic Obstructive Pulmonary Disease

目的观察肺胀宁煎治疗慢性阻塞性肺病急性加重期的临床疗效。方法选取2018年1月-2019年1月接受诊治的慢性阻塞性肺疾病急性加重期患者共计60例,采用信封法分为2组,对照组30例,应用左氧氟沙星注射液静点配合对症治疗,试验组30例,在对照组的基础上应用肺胀宁煎,观察2组患者血常规及治疗前后肺功能变化情况。结果治疗后2组血常规情况:白细胞试验组为:(7.21±2.7)×10^9/L,对照组为:(8.25±0.29)×10^9/L,中性粒细胞百分比试验组为:(57.3±10.2)%,对照组为(64.8±11.2)%,数据比较差异具有统计学意义(P<0.05)。治疗后肺功能水平试验组:(70.1±6.5)%对照组为:(61.4±8.6),明显高于对照组,2组数据比较有统计学差异(P<0.05),结论慢性阻塞性肺疾病急性加重期患者通过应用肺胀宁煎联合抗生素及对症支持治疗,可有效降低肺内炎性表现,有效恢复患者肺功能水平,提高临床疗效,控制病情,降低耐药性,临床疗效优异,值得临床推广。

Objective To observe the clinical effec t of Feizhangning decoction in treating acute exacerbation chronic obstructive pulmonary disease. Methods From January 2018 to January 2019, a total of 60 patients with acute exacerbation chronic obstructive pulmonary disease were treated in our hospital’s internal medicine ward and outpatient clinic. They were divided into two groups by envelope method. 30 cases in the control group were treated with levofloxacin injection and symptomatic therapy. 30 cases in the experimental group were treated with Feizhangning decoction on the basis of the control group. The changes of blood routine and pulmonary function before and after treatment were observed. Results The leukocyte of the experimental group and the control group was(7.21±2.7)×10^9/L and(8.25±0.29) ×10^9/L. Percentage of neutrophils of the experimental group and the control group was(57.3 ±10.2) % and(64.8±11.2) %, and the difference was statistically significant(P<0.05). Level of pulmonary function of the experimental group and the control group was(70.1±6.5) % and(61.4±8.6) %, the experimental group was better than the control group,, and the difference was statistically significant(P <0.05). Conclusion Feizhangning decoction combined with antibiotics and symptomatic supportive treatment can effectively reduce the expression of pulmonary inflammation in patients with acute exacerbation chronic obstructive pulmonary disease, which is worthy of clinical promotion.